Detection of Bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in Urine and Blood Specimens after Intravesical Immunotherapy for Bladder Carcinoma | Zendy

A. Siatelis | Zendy; Dimitra Houhoula | Zendy; Joseph Papaparaskevas | Zendy; Dimitrios Delakas | Zendy; Athanassios Tsakris | Zendy

Open Access

Detection of Bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in Urine and Blood Specimens after Intravesical Immunotherapy for Bladder Carcinoma

Author(s) -

A. Siatelis,

Dimitra Houhoula,

Joseph Papaparaskevas,

Dimitrios Delakas,

Athanassios Tsakris

Publication year - 2011

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.01595-10

Subject(s) - mycobacterium bovis , immunotherapy , medicine , bcg vaccine , urine , carcinoma , mycobacterium tuberculosis , tuberculosis , malignancy , mycobacterium tuberculosis complex , pathology , microbiology and biotechnology , biology , immunology , immune system

A real-time PCR targeting IS6110 was employed for the detection ofMycobacterium tuberculosis DNA in specimens collected from 10 patients treated with intravesicalM. bovis bacillus Galmette-Guérin (BCG) immunotherapy for bladder malignancy. BCG DNA was detected in all urine specimens taken 24 h after the instillations, as well as in 24% of the specimens collected 7 days after the instillations; it was also detected in a single specimen taken 6 weeks after the last instillation. BCG DNA was detected in 8.3% of the blood specimens taken 1 day after instillation, and its amplification was associated with cases of self-limiting fever. These findings give indications that this real-time PCR is helpful to recognize BCG bacteremic cases, which may lead to mycobacterial infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research